This work describes a novel surgical technique for extracapsular implantation of a personalized, 3-dimensional-printed, joint-preserving implant. This novel treatment aims to restore hip stability in young adult dogs suffering from hip dysplasia with laxity by uniquely reproducing the anatomical shape of the acetabular rim of the hip joint.
Hip dysplasia causes major disability in dogs. Treatment options are limited to palliative treatment (e.g., pain relief, physical exercise, lifestyle changes, and weight control) or invasive surgeries such as pelvic osteotomies and total hip arthroplasty. Hence, a strong unmet need exists for an effective and dog-friendly solution that enhances the quality of life of man's best friend. We fill this treatment gap by offering a minimally traumatic and extraarticular, dog-specific, 3-dimensional-printed, hip implant (3DHIP) that restores hip joint stability. The surgical treatment using a 3DHIP implant is less invasive than osteotomies and can be performed bilaterally in one surgical session. The 3DHIP implant extends the dorsal acetabular rim of the dysplastic hip joint thereby increasing coverage of the femoral head and inhibiting joint subluxation with fast recovery. Sufficient access to the dorsal acetabular rim and ventral border of the iliac body together with optimal fitting and fixation of the implant are key steps for a successful 3DHIP implantation and imply the need for a specific approach. The present article aims to showcase this innovative surgical technique with tips and tricks as a surgical manual for implantation of the 3DHIP implant in dogs affected by hip dysplasia.
Hip dysplasia (HD) in dogs manifests due to a bad fit between the hip socket (acetabulum) and the femoral head resulting in subluxation of the hip joint. It affects mainly young medium- to large-breed dogs, resulting in joint cartilage deterioration, and ultimately, severe osteoarthritis (OA) leading to chronic pain and low quality of life1,2. The overall prevalence of hip dysplasia in dogs is 15.56%, which varies widely based on breed and classification systems3,4.
Apart from lifestyle changes, hip dysplastic dog patients are treated with antiinflammatory and analgesic drugs to control pain and maintain mobility4. In case of hip laxity in young adult dogs, the only surgical resort is double (DPO) or triple pelvic osteotomy (TPO), a procedure involving two or three full cuts of the pelvic bones to expand the coverage of the femoral head. However, complications after osteotomies are common and the progression of OA is still observed5,6,7,8,9. Once severe OA and chronic pain have developed, only high-impact complex surgery like total hip replacement (THR) or salvage femoral head and neck ostectomy (FHO) remain10. However, FHO presents less favorable outcomes in large breed dogs and necessitates prolonged physical therapy for the restoration of limb function11. Furthermore, THR is technically challenging and inherently associated with severe complications12,13,14. Therefore, effective hip dysplasia therapy necessitating only low-impact surgery and with a lower complication risk is required before this end stage is achieved.
The 3-dimensional (3D)-printed personalized hip implant (3DHIP) is a first-of-a-kind treatment for canine hip dysplasia developed with the intention to offer a minimal traumatic dog-specific implant that restores hip joint stability. The technique involves a titanium implant to treat mainly young adult (6 months to 2 years old) dog patients with a dysfunctional hip joint showing hip laxity grade B (borderline) to D (moderate) according to the Fédération Cynologique Internationale (FCI)15. After computed tomography (CT) imaging of the dysplastic joint, an implant is designed following the specific anatomy of the hip joint in a personalized manner to extend the dorsal acetabular rim, thereby preventing hip joint subluxation and restoring hip joint stability.
A previous canine cadaver study revealed that the implant enhanced femoral head coverage and demonstrated failure under an impact force of 1,330 ± 320 Newtons16. Subsequently, a pilot study with experimental dogs demonstrated enhanced femoral head coverage, reduced hip laxity, and increased weight bearing by force plate analysis. Furthermore, examination of the intervened hips at 6 months post-implantation revealed normal volume and a smooth surface of both the femoral head and acetabulum cartilage, accompanied by joint capsule hypertrophy based on gross and histological assessments17. Upon confirmation of the efficacy and safety of the implant and treatment concept, a clinical investigation was carried out on client-owned dogs suffering from hip dysplasia. The short-term study revealed that the benefits of the 3D-printed acetabular rim extension implant are a personalized, good fit of the implant to the acetabulum restoring hip joint stability, decreased pain-related activities, and a low-impact surgical procedure18. Application of the implant requires access to the ventrocaudal aspect of the iliac body and the craniodorsal aspect of the hip joint. In this paper, we describe our surgical planning and surgical procedure with a modified craniodorsal approach to the hip joint as a manual for implantation of the 3DHIP in dogs affected by hip dysplasia.
This study was considered a non-experimental clinical veterinary practice as mentioned in Article 1 – 5(b) of Directive 2010/63/EU and was approved by the Veterinary Clinical Studies Committees (VCSC), Utrecht University, Utrecht, The Netherlands. This study involved the treatment of client-owned dogs, with all dogs continuing under the care of their respective owners. All dog owners were provided with an information letter detailing the study protocol, all potential complications (e.g., infection, implant failure, neurological deficits, and others), and alternative treatments like pelvic osteotomy. Furthermore, in this form, privacy aspects and inherent data management were explained. All clients signed an informed consent form. The entire protocol of this study is divided into the following major steps: patient selection, 3DHIP implant design and production, preoperative management and anesthesia, surgical procedure, and post-operative management.
1. Patient selection
2. 3DHIP implant design and production
3. Preoperative management and anesthesia
4. Surgical procedure
5. Postoperative management
Short-term results of acetabular rim extension have previously been published, arising from an ongoing observational study at the Utrecht University Department of Clinical Sciences18. From December 2019 to March 2022, a total of 61 hips from 34 dogs were included in the study. The cohort consisted of 24 males and 10 females, with a median age of 12 months (ranging from 7 to 38 months) and a median body weight of 27.3 kg (ranging from 12 to 86 kg). Seven dogs underwent surgery on a unilateral hip, while twenty dogs underwent bilateral hip surgery in a single session. Additionally, seven dogs received surgery on both hips, conducted in two separate sessions.
The previous study found a significant increase in the Norberg Angle (NA), linear percentage of femoral head coverage (LFO), and percentage of femoral head coverage (PC) immediately after implantation (Table 1). Moreover, the postoperative Ortolani subluxation sign was negative in 96.7% of operated limbs indicating that the acetabular rim extension implant restored hip congruency and diminished laxity of dysplastic hips18. Particularly, the ability to increase coverage of the femoral head without performing any re-directional osteotomy allowed physiological pelvic geometry retainment. The minimally invasive technique resulted in low incidences of complications (4.9%) in the short-term, encouraged early mobilization, and decreased pain related to activity (Table 1).
Furthermore, this technique allowed single-stage bilateral 3DHIP implant placement. Treated limb(s) were weightbearing without pelvic support within 12 to 24 h after surgery. During the 12-month monitoring period, 3 dogs required revision surgery due to either implant failure (2 dogs) or a significant advancement of osteoarthritis (1 dog). Using the presented surgical approach simultaneously with the suggested hip joint movements (abduction, flexion, and external rotation), better exposure of the ventrocaudal aspect of the iliac shaft and craniodorsal aspect of the hip joint was obtained, facilitating 3DHIP implant positioning. In addition, intra-operative fluoroscopy increased the accuracy of implant positioning.
Figure 1: Schematic illustrations showing a positive Ortolani subluxation sign counteracted by the 3DHIP implant. (A–D) Positive Ortolani subluxation sign. (A) The dog's limb is positioned in neutral flexion and adduction, and a force (red arrows) is exerted towards the dorsum of the dog along the femoral axis that causes (B) dorsal subluxation of the dysplastic hip joint. (C) Gradual limb abduction (blue arrow) is performed while maintaining pressure on the femur. (D) Dependent on the acetabular rim deficiency, the subluxated femoral head falls back into the socket (green arrows). (E) The 3DHIP implant is introduced to enhance the stability of the dysplastic hip joint by reinforcing the hip capsule and labrum, which serve as weight-bearing and stabilizing surfaces (purple arrows). (F) Upon magnification of the rectangular area, the internal 1.5 mm offset of the implant is visible in the red circle, which ensures the capsule attachment remains unaffected. This figure was modified from Willemsen et al.17. Abbreviation: 3DHIP = 3-dimensional-printed, hip implant. Please click here to view a larger version of this figure.
Figure 2: Example of the preoperative hip radiographs used for Fédération Cynologique Internationale hip dysplasia classification. Radiographs are taken in the ventro-dorsal hip extended position. From left to right, FCI classifies hip dysplasia into five different categories: A (normal), B (borderline), C (mild hip dysplasia), D (moderate hip dysplasia), and E (severe hip dysplasia). Abbreviation: FCI = Fédération Cynologique Internationale. Please click here to view a larger version of this figure.
Figure 3: Images of hip joint CT examinations illustrating osteophytes of varying sizes. The thickness of all featuring osteophytes is measured in both (A,B) coronal planes and (C) transverse planes at the cranial (white arrowhead) and caudal (red arrowhead) acetabular rim and femoral neck (black arrowhead). Dogs that have femoral neck and/or cranial and caudal acetabular rim osteophytes > 2 mm are excluded. CT examination slice thickness is 5 mm. Please click here to view a larger version of this figure.
Figure 4: Design process of 3DHIP implant. (A) Segmentation of the region of interest from CT DICOM data. (B) Measurements of the native Norberg angles on the 3D model of the pelvis. (C) Rendering of a 3DHIP implant on the right hip, lateral view. (D) Rendering of bilateral 3DHIP implants, dorsal-ventral view. Abbreviation: 3DHIP = 3-dimensional-printed, hip implant. Please click here to view a larger version of this figure.
Figure 5: Rendering of a designed 3DHIP implant. (A) Rendered image of the lateral/outer side of the 3DHIP implant. (B) Rendered image of the inner implant surface showing the porous surface allowing bone ingrowth for osseointegration. The bone attachment part (black arrowhead) of rendered implant incorporating 4 locking screw holes and the ventral ilium flange (black arrow) for assisting in correct implant positioning and stabilization. The rim extension part (red arrowhead) of the rendered implant with the internal 1.5 mm offset (red arrow) allowing unhindered joint capsule attachment. (C) Photograph of a titanium 3DHIP implant showcasing 4 screw holes arranged in the sequence for screw insertion. Abbreviation: 3DHIP = 3-dimensional-printed, hip implant. Please click here to view a larger version of this figure.
Figure 6: Schematic illustration of skin incision. (A) Red oval marks the area in which the skin incision is made. (B) Magnification of red circle in (A). The skin incision is made using a #10-blade centered on the tip of the greater trochanter aiming at the cranial dorsal iliac spine. The incision length is approximately 8-15 cm. In the magnified image, the superficial leaf of fascia latae is incised along the cranial muscle border of the biceps femoris muscle. Orientation: left is cranial, top is dorsal. Please click here to view a larger version of this figure.
Figure 7: Schematic illustrations and photographs of an embalmed cadaver depicting the surgical approach for 3DHIP implantation. (A–D) Schematic illustrations and (E–H) photographs of an embalmed cadaver depict the surgical approach for 3DHIP implantation. (A and E) The red dotted line marks the line of the incision through the intermuscular septum between the superficial gluteal muscle, middle gluteal muscle, and the tensor fascia latae muscle. (B and F) Red dotted line marks the tenotomy site. The superficial and middle gluteal muscles are retracted dorsally to expose the deep gluteal muscle. Dissecting scissors are used to undermine the deep gluteal muscle near its insertion on the greater trochanter. A tenotomy is performed close (at 0.5-1 cm) to its insertion on the bone. (C and G) Adequate exposure for 3DHIP implant placement requires freeing the deep gluteal muscle from the joint capsule and lateral surface of the iliac body and partially freeing the iliacus muscle and rectus femoris muscles from the caudoventral border of the ilial shaft (red dotted line). (D and H) The 3DHIP implant is placed outside the capsule of the hip joint. For accuracy and ease of positioning, the ilium flange of the attachment part of the implant is placed under the ventral border of the exposed caudoventral iliac shaft. Orientation: left is cranial, top is dorsal. 1) biceps femoris muscle, 2) tensor fascia latae muscle, 3) fatty triangle, 4) superficial gluteal muscle, 5) middle gluteal muscle, 6) deep gluteal muscle/tendon, 7) vastus lateralis muscle, 8) hip joint capsule, 9) articularis coxae muscle, 10) caudal part of iliac body, 11) rectus femoris muscle, 12) ilium flange of the implant, and 13) rim extension part of the implant. Please click here to view a larger version of this figure.
Figure 8: Intraoperative fluoroscopy. After implant positioning and temporary fixation with one locking screw, intraoperative fluoroscopy is performed in (A) lateral and (B) latero-oblique views using a digital image intensifier to assess and compare the positioning of the implant to the preoperative planning. Please click here to view a larger version of this figure.
Figure 9: Examples of postoperative radiographs in three planes and postoperative CT scan after single-stage bilateral 3DHIP implant surgery in one dog. (A) Radiograph ventrodorsal view; (B) radiograph right latero-oblique view; (C) radiograph left latero-oblique view. 3D reconstruction from post-operative CT in lateral view showing the (D) right hip and (E) dorso-ventral view. (F) Postoperative CT of both hips in the transverse plane with a slice thickness of 5 mm. The 3DHIP implants were fixed with four locking screws on each side. Please click here to view a larger version of this figure.
Outcome measurements | Preoperatively | Immediated postoperatively | 1.5 months | 3 months | p-value |
NA (◦) | 87 ± 13a | 134 ± 19b | – | 131 ± 20b | <0.001* |
LFO (%) | 22 ± 15a | 81 ± 16b | – | 76 ± 19b | <0.001* |
PC (%) | 33 ± 17a | 79 ± 21b | – | 77 ± 20b | 0.002* |
HCPI (%) | 31.44 ± 11.9a | – | 20.39 ± 10.09b | 17.69 ± 10.8b | <0.001** |
Table 1: Short-term results (Mean ± SD) of radiographic measurements using coronal CT and pain-related owner questionnaire using Helsinki Chronic Pain Index in dogs with hip dysplasia that underwent 3DHIP implantation. This table was modified from Kwananocha et al.18. HCPI (%) = 100% × total index score/maximum possible index score of the answered questions. a,bp-value < 0.05 from Bonferroni, p-value* from repeated measure analysis, p-value** from generalized linear mixed model. Abbreviations: NA = Norberg angle; LFO = linear percentage of femoral head overlap; PC = percentage of femoral head coverage; SD = standard deviation; HCPI = Helsinki Chronic Pain Index.
Supplementary Video S1: Direct postoperative weight-bearing allowed with only short leash walks on a slip-resistant floor from the day after surgery. Please click here to download this video.
Acetabular rim extension using the 3DHIP implant provides advantages over conventional surgical therapies for canine hip dysplasia and has shown promising results to increase coverage of the dysplastic hip joint and reverse hip laxity in short-term follow-up17,18. This publication aimed to showcase the surgical technique with tips and tricks as a surgical manual for implantation of the 3DHIP implant in dogs affected by hip dysplasia.
Selection of candidates for the 3DHIP implant placement-young dogs between 6 and 24 months of age with clinical hip dysplasia marked by hip laxity (FCI grade B-D) with a positive Ortolani subluxation test are adequate candidates. The triradiate acetabular growth plate has to be closed and preferably, no osteoarthritis is present on CT imaging although minor osteophytes up to 2 mm are accepted. Dogs with luxoid hips with near-complete luxation of the femoral head are not accepted for 3DHIP implant placement because of the rapid progression of osteoarthritis, the inability of the femoral head to move into the acetabulum, and expected early conversion to total hip replacement.
There are some critical steps within the surgical technique.
Implant design
Given the individualized design of the 3DHIP implants, a preoperative assessment of the dysplastic hip joint using a CT scan is absolutely mandatory. In addition to the determination of the correct implant size and position of the ventral ilial flange, particularly the amount of acetabular rim extension needed to provide sufficient coverage of the femoral head can be determined.
Surgical approach
A critical step during surgery is sufficient exposure of the dorsal acetabular rim and ventral border of the caudal iliac body for implant placement. The surgical approach to the iliac body and craniodorsal aspects of the hip joint in 3DHIP implantation differs from conventional approaches22. In the presented technique, a trochanteric osteotomy was omitted and a deep gluteal tenotomy was performed while the superficial and middle gluteal muscles were preserved. Hereby, the risk of complications associated with trochanteric osteotomies23,24,25 such as delayed or non-union were avoided and the recovery process was expedited. Additionally, this modified craniodorsal approach can be employed across a variety of ages, breeds, and sizes of dogs without any necessary modifications. Notably, no complications were reported in association with the presented surgical approach.
Correct implant placement
Even though the custom-made 3D-printed hip implant is designed to perfectly fit the unique acetabular anatomy of each dog, imperfect implant placement with 4-5 mm craniocaudal deviation to planning target position was still observed in the first cohort of dogs possibly related to the learning curve with the technique18. The ventral ilial flange of the bone attachment part of the 3DHIP implant allows for more accurate positioning, especially in the dorsoventral direction. However, due to the extracapsular location of the implant, it is still difficult to achieve perfect implant positioning; the inner edge of the acetabulum is obscured by the synovial membrane. Further, osteophyte formation during the lead time of implant production may influence proper implant positioning. To ensure accurate implant positioning according to the preoperative plan, verification using intraoperative fluoroscopy is currently required. It is also expected that with increased experience, the precision of implant positioning will further decrease to below 1-2 mm accurate placement. In the future, guided surgery using 3D-printed surgical drill guides may obviate the need for fluoroscopy.
This technique also has some limitations. Previous short-term results suggest a broad bandwidth of different hip anatomies that can be treated using 3DHIP implants. While the long-term study findings are not yet available, it is advised to consider 3DHIP implantation for dogs that do not exhibit signs of osteoarthritis (OA) or have only a mild degree of OA in their hip joints. The 3DHIP implant placement aims to effectively slow down the progression of hip joint deterioration. Dogs with luxoid hips and moderate to severe hip degeneration as determined in the pre-operative evaluation should be excluded.
Compared to 3DHIP implantation, conventional surgeries to treat canine hip dysplasia such as DPO/TPO present more challenges, especially in a single-stage bilateral procedure and/or in giant dogs due to their invasive nature involving two or three pelvic osteotomies5,6,7,26. Therefore, dogs with bilateral HD can benefit from an acetabular rim extension using a 3DHIP implant; it provides an effective and low invasive single-stage bilateral procedure. In addition, the 3DHIP implantation helps to save valuable time and can prevent the further development of OA that might occur in double-stage bilateral procedures.
To conclude, utilization of the presented 3DHIP implant to extend the dorsal acetabular rim exhibits significant promise as an alternative surgical treatment for hip dysplasia in canines. Especially, the option to offer an effective and low invasive single-stage bilateral procedure for dogs with bilateral hip dysplasia and laxity is an enormous advantage to current alternative treatments. Further monitoring of this new technique in mid- and long-term follow-up is mandatory.
The authors have nothing to disclose.
The present study was primarily financially supported by the foundation Vrienden Diergeneeskunde Universiteit Utrecht; MT has received long-term funding from the Dutch Arthritis Society (LLP22); FV and JM are funded by Eurostars Project E115515 – 3DHIP. IK is a holder of a scholarship from the Faculty of Veterinary Medicine, Kasetsart University, Thailand.
The laborotory for implant design | |||
3D Lab | University Medical Center Utrecht 3D, Utrecht, Netherlands | The laboratory responsible for designing the 3DHIP implant. [https://www.umcutrecht.nl/nl/3d-lab/] | |
Software | |||
3-Matic software version 17 | Materialise, Leuven, Belgium | CT DICOM data processing | |
Materialise Mimics software version 25.1 | Materialise, Leuven, Belgium | Software to design the 3DHIP implant on the 3D model of the pelvis | |
Implant manufacturer | |||
Amnovis | Amnovis, Aarschot, Belgium | Printing and postprocessing of the 3DHIP implant. [https://www.amnovis.com/] | |
Instrument and machine | |||
2.4 LeiLOX locking screw titanium | Rita Leibinger, BW, Germany | 242-224 | Titanium self tapping locking screw 2.4 mm. |
2.7 LeiLOX locking screw titanium | Rita Leibinger, BW, Germany | 242-227 | Titanium self tapping locking screw 2.7 mm. |
3.5 LeiLOX locking screw titanium | Rita Leibinger, BW, Germany | 242-235 | Titanium self tapping locking screw 3.5 mm. |
BLUE SEAL 100 x 360 mm | Interster, Wormerveer, Netherlands | 3FKFB210819 | The transparent sterilization laminate size 100 x 360 mm |
ETHILON 3-0 with FS-1 needle | Johnson & Johnson Medical GmbH, Norderstedt, Germany | 669H | Polyamide 6 3-0 (non-absorbable suture material) with 24 mm 3/8c reverse cutting needle using for skin closure |
Fluoroscopy model NZS 229 | Philips, Eindhoven, Netherlands | Fluoroscopy | |
Foley Catheter 10 fr x 90 cm (36") with 3 cc Balloon | MILA international inc., Kentucky, USA | MLIUC1036 | Foley urine catheter size 10 fr |
Foley Catheter 6 fr x 60 cm (24") with 3 cc Balloon | MILA international inc., Kentucky, USA | MLIUC624 | Foley urine catheter size 6 fr |
Foley Catheter 8 fr x 90 cm (36") with 3 cc Balloon | MILA international inc., Kentucky, USA | MLIUC836 | Foley urine catheter size 8 fr |
Ioban 2 | 3M, MN, USA | 6640EU | Iodine-impregnated surgical drape |
Miele professional G 7826 | Miele Nederland B.V., Vianen, Netherlands | The hygienic washing machine | |
MMM sterilizer OB10643 | MMM Group, Planegg, Germany | Steam autoclave | |
MONOCRYL 2-0 with SH Plus needle | Johnson & Johnson Medical GmbH, Norderstedt, Germany | MCP3170H | Poliglecaprone 25 plus antibacterial 2-0 (absorbable suture material) with 26 mm 1/2c taperpoint needle using for subcutaneous tissue closure |
MONOCRYL 3-0 with SH Plus needle | Johnson & Johnson Medical GmbH, Norderstedt, Germany | MCP3160H | Poliglecaprone 25 plus antibacterial 3-0 (absorbable suture material) with 26 mm 1/2c taperpoint needle using for subcutaneous tissue closure |
PDS 0 with CP needle | Johnson & Johnson Medical GmbH, Norderstedt, Germany | PDP485H | Polydioxanone plus antibacterial 0 (absorbable suture material) with 40 mm 1/2c reverse cutting needle using for muscle fascia and tendon closure |
PDS 2-0 with CP-1 needle | Johnson & Johnson Medical GmbH, Norderstedt, Germany | PDP466H | Polydioxanone plus antibacterial 2-0 (absorbable suture material) with 36 mm 1/2c reverse cutting needle using for muscle fascia and tendon closure |
ProX DMP320 | 3D systems, South Carolina, USA | Direct metal printing machine using selective laser melting technology | |
Medications | |||
Betadine oplossing | Mylan B.V., Amstelveen, Netherlands | RVG 01331 | Povidone-iodine solution 100 mg/mL (500 mL) |
Betadine shampoo | Mylan B.V., Amstelveen, Netherlands | RVG 08943 | Povidone-iodine 75 mg/mL (120 mL) |
Carporal 20 mg | AST Farma B.V. Oudewater, Netherlands | REG NL 101766 | Carprofen 20 mg/tablet |
Carporal 40 mg | AST Farma B.V. Oudewater, Netherlands | REG NL 115715 | Carprofen 40 mg/tablet |
Carporal 50 mg | AST Farma B.V. Oudewater, Netherlands | REG NL 101767 | Carprofen 50 mg/tablet |
Cefazolin Mylan 1 g | Mylan B.V., Amstelveen, Netherlands | RVG 16532 | Cefazolin powder 1 g for injection |
Chlorhexidine 0.5% in alcohol 70% spray | Orphi Farma BV, Lage Zwaluwe, Netherlands | 8711407672906 | Chlorhexidine 0.5% in alcohol 70% spray (250 mL) |
Dexdomitor 0.5 mg/mL | Orion Corporation, Espoo, Finland | EU/2/02/033/001-002 | Dexmedetomidine hydrochloride 0.5 mg/mL for injection (20 mL) |
Gabapentin Sandoz 300 mg | Sandoz B.V., Almere, Netherlands | RVG 33681 | Gabapentin 300 mg/capsule |
GABAPENTINE TEVA 100 mg | Teva B.V., Haarlem, Netherlands | RVG 31980 | Gabapentin 100 mg/capsule |
HiBiScrub | Mölnlycke Health Care AB., Utrecht, Netherlands | RVG 10156 | Chlorhexidine digluconate 40 mg/mL (500 mL) |
Insistor 10 mg/mL | Richter pharma AG, Oostenrijk, Netherlands | REG NL 121166 | Methadone hydrochloride 10 mg/mL for injection (10 mL) |
Isoflutek 1000 mg/g | Laboratorios Karizoo S.A., Barcelona, Spain | REG NL 118938 | Isoflurane 1000 mg/g (250 mL) |
Levobupivacaine Fresenius Kabi 2.5 mg/mL | Fresenius Kabi Nederland b.v., Huis ter Heide, Netherlands | AWA 0611 | Levobupivacaine 2.5 mg/mL solution for injection (10 mL) |
Morfine HCI CF 10 mg/mL | Centrafarm B.V., Breda, Netherlands | RVG 50836 | Morphine hydrochloride 10 mg/mL (1 mL) |
Narketan 10 | Vetoquinol B.V., Breda, Netherlands | vm08007/4090 | Ketamine 10 mg/mL (10 mL) |
Propofol 10 mg/mL | Fresenius Kabi Nederland b.v., Huis ter Heide, Netherlands | RVG 110627 | Propofol 10 mg/mL emulsion for injection or infusion (50 mL) |
Rimadyl | Zoetis B.V., Capelle a/d Ijssel, Netherlands | REG NL 10101 | Carprofen 50 mL/mL for injection (20 mL) |
Sufentanil-hameln 50 mcg/mL | Hameln pharma gmbh, Hameln, Germany | 4260016653249 | Sufentanil citrate 50 mcg/mL for injection |
Trazadone EG 100 mg | EG (Eurogenerics) NV Heizel, Brussel, Belgium | BE439607 | Trazadone hydrochloride 100 mg/tablet |